Advanced search
Start date
Betweenand

Development of vaccines based on recombinant BCG: Tuberculosis, Pertussis, Pneumococcus and Schistosoma

Grant number: 17/24832-6
Support type:Research Projects - Thematic Grants
Duration: November 01, 2018 - October 31, 2023
Field of knowledge:Biological Sciences - Biochemistry - Molecular Biology
Principal researcher:Luciana Cezar de Cerqueira Leite
Grantee:Luciana Cezar de Cerqueira Leite
Home Institution: Instituto Butantan. Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
Pesquisadores principais:
Viviane Maimoni Gonçalves
Assoc. researchers:Alex Issamu Kanno ; Celio Lopes Silva ; Dunia Del Carmen Rodriguez Soto ; Giovana Cappio Barazzone ; Helder Takashi Imoto Nakaya ; Ivan Pereira Nascimento ; Leonardo Paiva Farias ; Michelle Darrieux Sampaio Bertoncini ; Ricardo Carneiro Borra ; Richard Malley ; Robert Alan Wilson ; Sergio Costa Oliveira ; Sergio Verjovski Almeida
Associated scholarship(s):20/05589-6 - Immunological characterization of a recombinant BCG strain that simultaneously expresses mutant Pertussis toxin S1PT and adjuvant LTAK63 (rBCG-LTAK63-S1PT) for use as a bivalent vaccine to prevent Neonatal Pertussis and Tuberculosis, BP.DD
21/00145-5 - Development of a vaccine against the SARS-CoV-2 Coronavirus using the new antigen presenter system (MAPS - OMV), BP.TT
20/14758-6 - Development of a vaccine against the SARS-CoV-2 Coronavirus using the new Antigen Presenting System (MAPS - OMV), BP.PD
+ associated scholarships 20/07547-9 - Development of a vaccine against Coronavirus SARS-CoV-2 using a new antigen presenting system, BP.PD
20/02049-0 - Strategies for monitoring and controlling the cultivation of recombinant BCG-pertussis, BP.MS
19/25728-3 - Evaluation of the role of POLIAMINAS PotD transporter in the formation of biofilm in vitro by Streptococcus pneumoniae, BP.IC
19/06454-0 - Evaluation of BCG expressing adjuvant LTAK63 in a humanized mouse model as a therapeutic vaccine for Tuberculosis, BP.PD
19/02305-0 - Investigation of immune response mechanisms effective of a BCG Vaccine Recombinant against Tuberculosis by Systems Biology, BP.PD - associated scholarships

Abstract

Our studies have demonstrated the advantages of Mycobacterium bovis BCG as an antigen presenting system in the development of new vaccines. The project aims to expand the use of methods of heterologous gene expression in BCG developed in our laboratories with the aim of proposing new vaccines in the immunization against Pertussis, Tuberculosis, Pneumococcus and Schistosome, and to improve the immunotherapeutic treatment of Bladder Cancer. Some proposals are more advanced, such as the recombinant BCG (rBCG) vaccine against Neonatal Pertussis and the rBCG strain used for improved treatment against Bladder Cancer that are heading for clinical trials. The rBCG strain expressing an E. coli antigen as adjuvant, which was shown to induce greater protection against Tuberculosis, completed the proof of concept phase and it should be further characterized. The establishment of the CRISPR/Cas9 platform and the Systems Biology approach will boost these studies. We have extensive research on pneumococcal antigens under different forms of presentation. The association of this information with the advantages of rBCG has been shown to be a promising approach. Schistosoma functional genomics provided a number of genes / proteins that have been characterized as potential vaccine candidates, but require a more immunogenic presentation to the immune system. We will investigate new expression vectors in rBCG and a new strategy, MAPS (Multiple Antigen Presenting System), aiming to improve the induction of immune responses and protection. Immune responses induced by rBCG strains will be compared to other forms of antigen presentation in search for correlates of protection. The results of each of the subprojects are expected to generate effective immunobiologicals against major diseases in the public health context of the country to enable large-scale, low-cost production. (AU)

Articles published in Pesquisa para Inovação FAPESP about research grant:
FAPESP-funded startups are developing COVID-19 vaccines  
Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications (15)
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
MAMBELLI, FABIO; SANTOS, BRUNO P. O.; MORAIS, SUELLEN B.; GIMENEZ, ENRICO G. T.; ASTONI, DUANA C. DOS S.; BRAGA, AMANDA D.; FERREIRA, RAFAELA S.; AMARAL, FLAVIO A.; DE MAGALHAES, MARIANA T. Q.; C. OLIVEIRA, SERGIO. S. mansoni SmKI-1 Kunitz-domain: Leucine point mutation at P1 site generates enhanced neutrophil elastase inhibitory activity. PLoS Neglected Tropical Diseases, v. 15, n. 1 JAN 2021. Web of Science Citations: 0.
DE QUEIROZ, NINA MARI G. P.; MARINHO, FABIO V.; CHAGAS, MARCELO A.; LEITE, LUCIANA C. C.; HOMAN, E. JANE; DE MAGALHAES, MARIANA T. Q.; OLIVEIRA, SERGIO C. Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system. Microbes and Infection, v. 22, n. 10, p. 515-524, NOV-DEC 2020. Web of Science Citations: 0.
SANCHES, RODRIGO C. O.; SOUZA, CLAUDIA; OLIVEIRA, SERGIO C. Schistosoma antigens as activators of inflammasome pathway: from an unexpected stimulus to an intriguing role. Microbes and Infection, v. 22, n. 10, p. 534-539, NOV-DEC 2020. Web of Science Citations: 0.
OLIVEIRA, SERGIO C.; DE MAGALHAES, MARIANA T. Q.; HOMAN, E. JANE. Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets. FRONTIERS IN IMMUNOLOGY, v. 11, OCT 28 2020. Web of Science Citations: 0.
ELIZAGARAY, MAIA L.; GOMES, MARCO TULIO R.; GUIMARAES, ERIKA S.; RUMBO, MARTIN; HOZBOR, DANIELA F.; OLIVEIRA, SERGIO C.; MORENO, GRISELDA. Canonical and Non-canonical Inflammasome Activation by Outer Membrane Vesicles Derived FromBordetella pertussis. FRONTIERS IN IMMUNOLOGY, v. 11, AUG 20 2020. Web of Science Citations: 0.
MARINHO, FABIO V.; FAHEL, JULIA S.; DE ARAUJO, ANA CAROLINA V. S. C.; DINIZ, LUNNA T. S.; GOMES, MARCO T. R.; RESENDE, DANILO P.; JUNQUEIRA-KIPNIS, ANA P.; OLIVEIRA, SERGIO C. Guanylate binding proteins contained in the murine chromosome 3 are important to control mycobacterial infection. Journal of Leukocyte Biology, JUL 2020. Web of Science Citations: 0.
SANCHES, RODRIGO C. O. The role of the adaptor molecule STING during Schistosoma mansoni infection. SCIENTIFIC REPORTS, v. 10, n. 1 MAY 13 2020. Web of Science Citations: 1.
SANCHES, RODRIGO C. O.; SOUZA, CLAUDIA; MARINHO, FABIO VITARELLI; MAMBELLI, FABIO SILVA; MORAIS, SUELLEN B.; GUIMARAES, ERIKA S.; OLIVEIRA, SERGIO COSTA. NLRP6 Plays an Important Role in Early Hepatic Immunopathology Caused by Schistosoma mansoni Infection. FRONTIERS IN IMMUNOLOGY, v. 11, MAY 5 2020. Web of Science Citations: 0.
GOULART, CIBELLY; RODRIGUEZ, DUNIA; KANNO, I, ALEX; SILVA, JOSE LOURENCO S. C.; LEITE, LUCIANA C. C. Early pneumococcal clearance in mice induced by systemic immunization with recombinant BCG PspA-PdT prime and protein boost correlates with cellular and humoral immune response in bronchoalveolar fluids (BALF). VACCINE: X, v. 4, APR 9 2020. Web of Science Citations: 0.
MAMBELLI, F. S.; FIGUEIREDO, B. C.; MORAIS, S. B.; ASSIS, N. R. G.; FONSECA, C. T.; OLIVEIRA, S. C. Recombinant micro-exon gene 3 (MEG-3) antigens from Schistosoma mansoni failed to induce protection against infection but show potential for serological diagnosis. Acta Tropica, v. 204, APR 2020. Web of Science Citations: 0.
OLIVEIRA, F. M.; MARINHO, F. V.; OLIVEIRA, S. C.; RESENDE, D. P.; JUNQUEIRA-KIPNIS, A. P.; KIPNIS, A. Mycobacterium abscessus subsp. massiliense expressing bacterioferritin have improved resistance to stressful conditions. Journal of Applied Microbiology, v. 128, n. 6 FEB 2020. Web of Science Citations: 0.
CONVERSO, T. R.; ASSONI, L.; ANDRE, G. O.; DARRIEUX, M.; LEITE, L. C. C. The long search for a serotype independent pneumococcal vaccine. EXPERT REVIEW OF VACCINES, v. 19, n. 1 JAN 2020. Web of Science Citations: 0.
LARISSA V NASCIMENTO; CARINA C SANTOS; LUCIANA CC LEITE; IVAN P NASCIMENTO. Characterisation of alternative expression vectors for recombinant Bacillus Calmette-Guérin as live bacterial delivery systems. Memórias do Instituto Oswaldo Cruz, v. 115, p. -, 2020.
DOS SANTOS, CARINA CARVALHO; RODRIGUEZ, DUNIA; ISSAMU, ALEX KANNO; DE CERQUEIRA LEITE, LUCIANA CEZAR; NASCIMENTO, IVAN PEREIRA. Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria. HUMAN VACCINES & IMMUNOTHERAPEUTICS, v. 16, n. 3, p. 673-683, 2020. Web of Science Citations: 0.
RODRIGUEZ, DUNIA; GOULART, CIBELLY; PAGLIARONE, ANA C.; SILVA, ELIANE P.; CUNEGUNDES, PRISCILA S.; NASCIMENTO, IVAN P.; BORRA, RICARDO C.; DIAS, WALDELY O.; TAGLIABUE, ALDO; BORASCHI, DIANA; LEITE, LUCIANA C. C. In vitro Evidence of Human Immune Responsiveness Shows the Improved Potential of a Recombinant BCG Strain for Bladder Cancer Treatment. FRONTIERS IN IMMUNOLOGY, v. 10, JUN 26 2019. Web of Science Citations: 3.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.